Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Antiviral Activity of ABI-4334 in Chronic Hepatitis B
NCT06384131Phase 1Completed
- Sponsor
- Assembly Biosciences, Inc.
- Start
- Jun 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ABI-4334 with Placebo (2 arms). Primary endpoint: Safety and tolerability of ABI-4334 at 56 days. Started Jun 2024; status: completed.
02
Drugs
ABI-4334
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06384131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06384131.